Founder, President & CEO
Robert DiCrisci is the Founder and CEO of
NextSource Biotechnology (NSB), a sister company
of Amatheon Pharmaceuticals. Mr. DiCrisci has over 18 years of experience in the healthcare and pharmaceuticals industry. He began his
career being recruited by Microsoft while still in his second year of college, immediately rising to become one of their top field
consultants working on projects at the C-level in organizations like Cosabella Inc., Health Coalition, University of Michigan Health Systems,
AAA Auto Club Group, HRH Construction and Sirco Associates.
Before founding Amatheon, Mr. DiCrisci served as Executive Director of Medical Staffing Network (MSN), which was the largest publicly traded medical
staffing firm in the U.S., with revenues of more than $500 million. After leaving MSN, he founded Amatheon Pharmaceuticals and spent over 13 years
building it into the leading distributor of hard-to-find human drugs for the veterinary market. His decade plus of experience in dealing with the
difficulties of vet practitioners face with various short supply human drugs is what prompted him to found NextSource, which is dedicated to
consolidating human-to-vet “Cross-Over” medications (and their supply chains) for the benefit of the veterinary market.
Mr. DiCrisci graduated Summa Cum Laude from the University of Central Florida, with a Bachelor of Business Administration (BBA) in Finance &
Marketing. He has been a Microsoft Certified Systems Engineer (MCSE) since 1998 and he has been the Licensed DEA Registrant for Amatheon and
NextSource Biotech since 2008.
Chris F. Yankana
Chief Financial Officer
Chris Yankana is the Chief Financial Officer (CFO) of
NextSource Biotechnology (NSB). Mr. Yankana has over 20 years of experience in the healthcare
and pharmaceutical industry as CFO, Controller, Auditor and Sales Manager. As the CFO for NextSource, he plays a vital role in developing and
implementing the national strategies, financial planning, purchasing programs. He also serves as an advisor to all department including the
Sales/Marketing initiatives. He is responsible for overseeing all fiscal and fiduciary responsibilities for NextSource Biotechnology and its subsidiaries.
Mr. Yankana is the Resident Certified Designated Representative and is also a Certified Public Accountant (CPA). His experience includes positions
as the Controller then Sales Manager for Health Coalition; prior to this he served as an Accounting Auditor for several large NYC companies.
Kevin a. Hahn, DVM, PHD, DACVIM
Chief Scientific Officer, Executive Vice President
Kevin A. Hahn, DVM, PhD, DACVIM (Oncology) is Chief Scientific Officer (CSO) and Executive Vice President
for NextSource Biotechnology (NSB).
Dr. Hahn has over 25 years of experience in the veterinary healthcare, nutrition, and pharmaceutical industry. As CSO he leads the NextSource
Biotechnology global new product pre-clinical development and regulatory approval strategy and serves as a key advisor during the development
and implementation of Sales/Marketing initiatives.
Prior to joining NextSource Biotechnology he served as Chief Medical Officer for Hill’s Pet Nutrition, Inc. (Topeka, KS); Senior Partner
for Gulf Coast Veterinary Oncology & Diagnostic Imaging (Houston, TX); and Associate Professor of Medical Oncology, University of Tennessee (Knoxville, TN).
Dr. Hahn is an entrepreneur, scientist, veterinarian, and community supporter. He actively participates in causes that enrich the human-animal bond as well
as the human-spiritual bond. He is recognized internationally in the discipline of veterinary medical oncology, companion animal nutrition, comparative biosciences,
and is an active leader in the animal health industry.
Richard C. Dinovitz
Chief Commercial Officer & Executive Vice President
Richard Dinovitz is Chief Commercial Officer (CCO) and
Executive Vice President for NextSource Biotechnology (NSB).
Richard has over 35 years of experience in the vaccine, biological, biotech, and pharmaceutical industries. As CCO
he is responsible for the NextSource Biotechnology global strategy and the development of the organization to drive
business growth and market share.
Richard is an accomplished sales and marketing officer-level executive with wide-ranging experience in complex technical
markets. He is a creative thinker equally comfortable in strategic planning, business development product launches,
commercial team management and leadership. He is a serial entrepreneur experienced in company startups, venture funding,
co-promotions, mergers and acquisitions. Richard is a business executive who understands the need to exceed expectations
as well as to over achieve aggressive targets.
Richard spent over 30 years in positions of increasing responsibility with Pfizer where he consistently delivered strong
financial growth through building high performing teams, identifying/capitalizing on business and product specification
opportunities, expanding distribution channels/networks, launching new products, and developing innovative marketing
strategies. Additionally, he gained considerable expertise in government negotiation, commercial operations, strategic
alliance management, and contracting.
As Vice President, Business Development at a start-up company, Nuron Biotech, Richard impressively led the company's effort
to acquire five pharmaceutical and vaccine products within a two year period. He successfully worked with investors to secure
sufficient capital to ensure appropriate funding of the company.
Richard has founded two companies, Vaccines Business Logistics and RCDVaccine, LLC where he has served as President and COO.
These companies were launched to help increase patient access to important vaccines, enhance immunization rates, and to provide
a brokerage of products and services for companies within the vaccines industry. These companies serve to offer exemplary
consulting services to vaccine providers, manufacturers, and suppliers to meet both commercial and philanthropic goals.
Richard received his B.S degree from the University of Pittsburgh. Richard remains active in various Trade Organizations and
Director of Strategic Planning & Market Access
Mr. Raul Armand brings over 30 years of executive experience in the pharmaceutical industry. He has extensive knowledge and understanding of the industry across
numerous therapeutic areas including Dermatology, Hematology/Oncology, specifically in; Lymphomas/Leukemia’s, Genitourinary, Gynecological, Colorectal
Head and Neck and Breast Cancers. As the NextSource Biotechnology (NSB) Director of Strategic Planning and Market Access
he is responsible for identifying and implementing programs which support our portfolio of products by all stakeholders. He also works across
platforms, both internal and external, to ensure flawless execution of our Access Strategy. Mr. Armand was instrumental during the formative phase of the company by
helping to develop the structural foundation of NextSource Biotechnology.
Raul Armand graduated from Florida State University with a Bachelor of Business Administration in Marketing and Communications. During his stellar career
at Bristol-Myers Squibb in Direct Marketing and Training he won numerous awards and was inducted into “Grand Master.” Throughout the years he served as a
mentor to many colleagues and as a consultant to senior management and brand agencies. Raul lives in Miami, is married and has two daughters, he volunteers
his time and talents with a local Non-Profit helping orphaned and abandoned children.